Journal profile · Pharmacology & Pharmacy
Personalized Medicine
ISSN 1741-0541 · eISSN 1744-828X · Future Medicine Ltd. · ENGLAND · Quarterly · Founded 2004
Personalized Medicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.19; hybrid open access; median 147 days to acceptance (92 articles, last 24 months); community-reported acceptance: fairly easy; 51 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Personalized Medicine is published by Future Medicine Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are BRCA gene mutations in cancer, Pharmacogenetics and Drug Metabolism and Genomics and Rare Diseases, together about 30.8% of its articles. Its main subfields are Genetics. (generated from OpenAlex topic counts and CAS ranking data)
Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- BRCA gene mutations in cancerBiochemistry, Genetics and Molecular Biology11.8%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics10%
- Genomics and Rare DiseasesBiochemistry, Genetics and Molecular Biology9%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6.8%
- Ethics in Clinical ResearchMedicine5.5%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance5.1%
- Nutrition, Genetics, and DiseaseBiochemistry, Genetics and Molecular Biology4.9%
- Bioinformatics and Genomic NetworksBiochemistry, Genetics and Molecular Biology4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.19LetPub ·
- CiteScore 2026-06
- 2.7LetPub ·
- SJR 2026-06
- 0.36LetPub ·
- SNIP 2026-06
- 0.35LetPub ·
- h-index
- 24LetPub ·
- h-index
- 50OpenAlex ·
- i10-index
- 416OpenAlex ·
- 2-year mean citedness
- 1.33OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 8.94%LetPub ·
Volume
- Articles per year
- 49LetPub ·
Articles by year OpenAlex count · 1,519 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 37 | 1 | 5 |
| 2025 | 51 | 18 | 89 |
| 2024 | 34 | 2 | 68 |
| 2023 | 45 | 14 | 215 |
| 2022 | 49 | 13 | 374 |
| 2021 | 60 | 22 | 534 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
147 daysMedian, submission to acceptance · P25–P75 101 days – 187 days
- Acceptance to online
- median 11 days (92 articles)
- Submission to online
- median 160 days
- Sample
- 92 articles with submission and acceptance dates (98 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Future Medicine Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 2004
- ISSN
- 1741-0541
- Electronic ISSN
- 1744-828X
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Personalized Medicine
What CAS zone is Personalized Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Personalized Medicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Personalized Medicine?
The latest impact factor listed by LetPub is 1.19; CiteScore 2.7, h-index 50.
How long does peer review take at Personalized Medicine?
Based on the dates recorded on 92 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 147 days (interquartile range 101–187 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Personalized Medicine?
According to LetPub and DOAJ records, Personalized Medicine is indexed in SCIE and Scopus.
Is Personalized Medicine open access, and what is the APC?
Personalized Medicine is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .